Search

Displaying results 4281 - 4290 of 10000 in total
  1. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.

  2. Drug

    TAS-106

    go.drugbank.com/drugs/DB06656
    Investigational

    TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

  3. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.

  4. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis.

  5. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

    Synonyms: 3,4-Methylenedioxy-N-isopropylamphetamine
  6. Drug

    Estrone sulfate

    go.drugbank.com/drugs/DB04574
    Approved

    men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis. … some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in

  7. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  8. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    The IL13 portion binds to receptors on the tumor.

  9. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  10. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants